Different cardiovascular drugs and their potential effects on liver
| Potential liver injury effects | |
| Cardiovascular drugs | |
| Amiodaron | Centrilobular necrosis |
| Quinidine | Hypersensitivity reaction |
| Procainamide | Delayed drug hypersensitivity |
| Propafenone | Hepatocellular and cholestatic liver injury |
| Flecainide | Hepatocellular injury |
| Dysopiramide | Hepatocellular damage, intrahepatic cholestasis |
| AntiPlt | Mostly hepatocellular damage |
| Statins | Hepatocellular necrosis |
| Fibrate | Hepatocellular injury |
| Niacin | Hepatocellular and cholestatic injury |
| Ezetimibe | Hepatotoxicity in combination with statins |
| Ca channel blockers | Hepatocellular injury |
| Warfarin | Rare but cholestatic type |
| Heparin | Mild elevation in aminotransferase levels |
| Enoxaparin | Mostly hepatocellular |
| HF therapies | |
| ACE inhibitors | Cholestatic injury |
| β-Blockers | Hepatocellular injury |
| ARB | Cholestatic injury and/or hepatocellular injury |
| Loop diuretics | Cholestatic injury |
| Thiazides | Mixed hepatocellular and cholestatic injury |
| Hydralazin | Hepatocellular injury |
| Aldostrone antagonists | Elevated aminotransferase |
| Antidiabetics | |
| Insulin | Elevation in γ-glutamyl transpeptidase |
| Glibenclamide | Mixed pattern of liver injury |
| Glithazones | Mostly hepatocellular injury |
ARB, agniotensin receptor blocker; HF, heart failure.